



# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 11-Oct-2022

Revision Number 2

**73402 73404 - Ruxolitinib**

## Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

### 1.1. Product identifier

Document Number DX21209

Product Name Ruxolitinib

Synonyms INC 424; INCB 018424;

Pure substance/mixture Substance

Contains (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile

Molecular weight 306.4

### 1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Laboratory chemicals

Uses advised against No information available

### 1.3. Details of the supplier of the safety data sheet

#### **Manufacturer**

STEMCELL Technologies SARL  
40 Rue des Berges, Miniparc Polytec, Bâtiment Sirocco, 38000 Grenoble, France  
+33 (0) 4 76 04 75 30  
STEMCELL Technologies Germany GmbH  
Stolberger Str. 200, 50933, Köln, Germany  
+33 (0) 4 76 04 75 30  
STEMCELL Technologies UK Ltd.  
Building 7100, Cambridge Research Park, Beach Drive, Waterbeach, Cambridge, UK, CB25 9TL  
+33 (0) 4 76 04 75 30

For further information, please contact

### 1.4. Emergency telephone number

Emergency Telephone No information available

Emergency Telephone - \$45 - (EC)1272/2008

Europe 112

## Section 2: HAZARDS IDENTIFICATION

### 2.1. Classification of the substance or mixture



# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 11-Oct-2022

Revision Number 2

## 73402 73404 - Ruxolitinib

Regulation (EC) No 1272/2008

Acute toxicity - Oral	Category 4 - (H302)
Serious eye damage/eye irritation	Category 1 - (H318)
Reproductive toxicity	Category 2 - (H361)
Specific target organ toxicity (repeated exposure)	Category 2 - (H373)

### 2.2. Label elements

Contains (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile



### Signal word

Danger

### Hazard statements

#### Hazard statements

H302 - Harmful if swallowed

H318 - Causes serious eye damage

H361 - Suspected of damaging fertility or the unborn child

H373 - May cause damage to organs through prolonged or repeated exposure

H303 - May be harmful if swallowed

### Precautionary Statements - EU (§28, 1272/2008)

P280 - Wear eye protection/ face protection

P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing

P310 - Immediately call a POISON CENTER or doctor

P201 - Obtain special instructions before use

P202 - Do not handle until all safety precautions have been read and understood

P280 - Wear protective gloves/protective clothing/eye protection/face protection

P308 + P313 - IF exposed or concerned: Get medical advice/attention

P260 - Do not breathe dust/fume/gas/mist/vapors/spray

P314 - Get medical advice/attention if you feel unwell

P501 - Dispose of contents/container to industrial incineration plant

### Additional information

This product requires tactile warnings if supplied to the general public

### 2.3. Other hazards

No information available

## Section 3: COMPOSITION/INFORMATION ON INGREDIENTS



# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 11-Oct-2022

Revision Number 2

**73402 73404 - Ruxolitinib**

## 3.1 Substances

Chemical name	EC No.	CAS No.	Weight-%	Classification according to Regulation (EC) No. 1272/2008 [CLP]	REACH Registration Number
(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile	-	941678-49-5	100	Acute Toxicity – Oral – Acute Tox. 4 (H302) Serious Eye Damage – Eye Dam. 1 (H318) Reproductive Toxicity – Repr. 2 (H361) Specific Target Organ Toxicity – Repeated Exposure – STOT RE 2 (H373)	No data available

Full text of H- and EUH-phrases: see section 16

## Section 4: FIRST AID MEASURES

### 4.1. Description of first aid measures

<b>General advice</b>	Immediate medical attention is required. Show this safety data sheet to the doctor in attendance.
<b>Inhalation</b>	Remove to fresh air. Get medical attention immediately if symptoms occur.
<b>Eye contact</b>	Get immediate medical advice/attention. Rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Keep eye wide open while rinsing. Do not rub affected area.
<b>Skin contact</b>	Wash off immediately with soap and plenty of water for at least 15 minutes. Get medical attention if irritation develops and persists.
<b>Ingestion</b>	Clean mouth with water and drink afterwards plenty of water. Never give anything by mouth to an unconscious person. Do NOT induce vomiting. Call a physician.
<b>Self-protection of the first aider</b>	Avoid contact with skin, eyes or clothing. Wear personal protective clothing (see section 8).

### 4.2. Most important symptoms and effects, both acute and delayed

<b>Symptoms</b>	Burning sensation.
-----------------	--------------------

### 4.3. Indication of any immediate medical attention and special treatment needed



# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 11-Oct-2022

Revision Number 2

**73402 73404 - Ruxolitinib**

**Note to physicians**

Treat symptomatically.

## Section 5: FIRE-FIGHTING MEASURES

### 5.1. Extinguishing media

**Suitable Extinguishing Media**

Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

**Unsuitable Extinguishing Media**

No information available.

### 5.2. Special hazards arising from the substance or mixture

**Specific hazards arising from the chemical**

No information available.

### 5.3. Advice for firefighters

**Special protective equipment for fire-fighters**

Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

## Section 6: ACCIDENTAL RELEASE MEASURES

### 6.1. Personal precautions, protective equipment and emergency procedures

**Personal precautions**

Avoid contact with skin, eyes or clothing. Ensure adequate ventilation. Use personal protective equipment as required. Evacuate personnel to safe areas.

**Other Information**

Refer to protective measures listed in Sections 7 and 8.

**For emergency responders**

Use personal protection recommended in Section 8.

### 6.2. Environmental precautions

**Environmental precautions**

Prevent further leakage or spillage if safe to do so.

### 6.3. Methods and material for containment and cleaning up

**Methods for containment**

Prevent further leakage or spillage if safe to do so.

**Methods for cleaning up**

Take up mechanically, placing in appropriate containers for disposal.

**Prevention of secondary hazards**

Clean contaminated objects and areas thoroughly observing environmental regulations.

### 6.4. Reference to other sections



## SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 11-Oct-2022

Revision Number 2

**73402 73404 - Ruxolitinib**

**Reference to other sections** See section 8 for more information. See section 13 for more information.

### Section 7: HANDLING AND STORAGE

#### 7.1. Precautions for safe handling

**Advice on safe handling** Avoid contact with skin, eyes or clothing. Do not eat, drink or smoke when using this product. Remove contaminated clothing and shoes. Handle in accordance with good industrial hygiene and safety practice. Ensure adequate ventilation.

**General hygiene considerations** Avoid contact with skin, eyes or clothing. Wear suitable gloves and eye/face protection. Do not eat, drink or smoke when using this product. Wash hands before breaks and immediately after handling the product.

#### 7.2. Conditions for safe storage, including any incompatibilities

**Storage Conditions** Keep out of the reach of children. Store locked up. Store in accordance with information listed on the Product Information Sheet (PIS).

#### 7.3. Specific end use(s)

**Identified Uses**

**Risk Management Methods (RMM)** The information required is contained in this Material Safety Data Sheet.

### Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

#### 8.1. Control parameters

**Exposure Limits** This product, as supplied, does not contain any hazardous materials with occupational exposure limits established by the region specific regulatory bodies.

**Derived No Effect Level (DNEL)** No information available.

**Predicted No Effect Concentration (PNEC)** No information available.

#### 8.2. Exposure controls

**Personal protective equipment**



# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 11-Oct-2022

Revision Number 2

## 73402 73404 - Ruxolitinib

Eye/face protection	Tight sealing safety goggles.
Hand protection	Wear suitable gloves.
Skin and body protection	Wear suitable protective clothing.
Respiratory protection	No protective equipment is needed under normal use conditions. If exposure limits are exceeded or irritation is experienced, ventilation and evacuation may be required.
General hygiene considerations	Avoid contact with skin, eyes or clothing. Wear suitable gloves and eye/face protection. Do not eat, drink or smoke when using this product. Wash hands before breaks and immediately after handling the product.
Environmental exposure controls	No information available.

## Section 9: PHYSICAL AND CHEMICAL PROPERTIES

### 9.1. Information on basic physical and chemical properties

Physical state	Solid
Appearance	Crystalline
Color	No information available
Odor	No data available.
Odor threshold	No data available

Property	Values	Remarks • Method
pH	No data available	None known
Melting point / freezing point	No data available	None known
Boiling point / boiling range	No data available	None known
Flash point	No data available	None known
Evaporation rate	No data available	None known
Flammability (solid, gas)	No data available	None known
Flammability Limit in Air	No data available	None known
Upper flammability limit:	No data available	
Lower flammability limit:	No data available	
Vapor pressure	No data available	None known
Vapor density	No data available	None known
Relative density	No data available	None known
Water solubility	No data available	None known
Solubility(ies)	No data available	None known
Partition coefficient	No data available	None known
Autoignition temperature	No data available	None known
Decomposition temperature	No data available	None known
Kinematic viscosity	No data available	None known



# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 11-Oct-2022

Revision Number 2

## 73402 73404 - Ruxolitinib

Dynamic viscosity	No data available	None known
Explosive properties	No information available	
Oxidizing properties	No information available	
<b>9.2. Other information</b>		
Softening point	No information available	
Molecular weight	306.4	
Molecular formula	C17H18N6	
VOC Content (%)	No information available	
Liquid Density	No information available	
Bulk density	No information available	

## Section 10: STABILITY AND REACTIVITY

### 10.1. Reactivity

Reactivity No information available.

### 10.2. Chemical stability

Stability Stable under recommended transport or storage conditions.

### Explosion data

Sensitivity to Mechanical Impact None.

Sensitivity to Static Discharge None.

### 10.3. Possibility of hazardous reactions

Possibility of hazardous reactions None under normal processing.

### 10.4. Conditions to avoid

Conditions to avoid None known based on information supplied.

### 10.5. Incompatible materials

Incompatible materials Strong acids. Avoid release into the environment. Strong oxidizing agents.

### 10.6. Hazardous decomposition products

Hazardous decomposition products Carbon monoxide. Carbon dioxide (CO<sub>2</sub>). Hydrogen cyanide. Nitrogen oxides (NO<sub>x</sub>).

## Section 11: TOXICOLOGICAL INFORMATION



# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 11-Oct-2022

Revision Number 2

**73402 73404 - Ruxolitinib**

## 11.1. Information on toxicological effects

### Information on likely routes of exposure

#### Product Information

Inhalation	Specific test data for the substance or mixture is not available.
Eye contact	Specific test data for the substance or mixture is not available. Severely irritating to eyes. Causes serious eye damage. May cause burns. May cause irreversible damage to eyes.
Skin contact	Specific test data for the substance or mixture is not available. May cause irritation.
Ingestion	Ingestion may cause gastrointestinal irritation, nausea, vomiting and diarrhea. Specific test data for the substance or mixture is not available. Harmful if swallowed. (based on components).

### Symptoms related to the physical, chemical and toxicological characteristics

Symptoms	Redness. Burning. May cause blindness.
----------	--

### Numerical measures of toxicity

#### Acute toxicity

The following values are calculated based on chapter 3.1 of the GHS document

ATEmix (oral) 500.00 mg/kg

Unknown acute toxicity 100 % of the mixture consists of ingredient(s) of unknown toxicity.

0 % of the mixture consists of ingredient(s) of unknown acute oral toxicity.

100 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity.

100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas).

100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor).

100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist).

Product Information

### Delayed and immediate effects as well as chronic effects from short and long-term exposure

Skin corrosion/irritation	May cause skin irritation.
---------------------------	----------------------------

Product Information

Serious eye damage/eye irritation	Classification based on data available for ingredients. Causes burns. Risk of serious damage to eyes.
-----------------------------------	---

Product Information





# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 11-Oct-2022

Revision Number 2

**73402 73404 - Ruxolitinib**

**Respiratory or skin sensitization** No information available.

Product Information

**Germ cell mutagenicity** No information available.

Product Information

**Carcinogenicity** No information available.

Product Information

**Reproductive toxicity** Classification based on data available for ingredients.

Product Information

**STOT - single exposure** No information available.

Product Information

**STOT - repeated exposure** May cause damage to organs.

Product Information

**Aspiration hazard** No information available.

## Section 12: ECOLOGICAL INFORMATION

### 12.1. Toxicity

**Ecotoxicity** The environmental impact of this product has not been fully investigated.

**Unknown aquatic toxicity** Contains 0 % of components with unknown hazards to the aquatic environment.

Product Information

### 12.2. Persistence and degradability

**Persistence and degradability** No information available.

### 12.3. Bioaccumulative potential

**Bioaccumulation** No information available.

### 12.4. Mobility in soil

**Mobility in soil** No information available.

### 12.5. Results of PBT and vPvB assessment

**PBT and vPvB assessment** No information available.



# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 11-Oct-2022

Revision Number 2

**73402 73404 - Ruxolitinib**

## 12.6. Other adverse effects

Other adverse effects No information available.

## Section 13: DISPOSAL CONSIDERATIONS

### 13.1. Waste treatment methods

Waste from residues/unused products Dispose of in accordance with local regulations. Dispose of waste in accordance with environmental legislation.

Contaminated packaging Do not reuse empty containers.

## Section 14: TRANSPORT INFORMATION

### IMDG

14.1 UN Number Not regulated  
 14.2 UN proper shipping name Not regulated  
 14.3 Transport hazard class(es) Not regulated  
 14.4 Packing Group Not regulated  
 14.5 Marine pollutant Not applicable  
 14.6 Special Provisions None  
 14.7 Transport in bulk according to Annex II of MARPOL and the IBC Code No information available

### RID

14.1 UN Number Not regulated  
 14.2 UN proper shipping name Not regulated  
 14.3 Transport hazard class(es) Not regulated  
 14.4 Packing Group Not regulated  
 14.5 Environmental hazard Not applicable  
 14.6 Special Provisions None

### ADR

14.1 UN Number Not regulated  
 14.2 UN proper shipping name Not regulated  
 14.3 Transport hazard class(es) Not regulated  
 14.4 Packing Group Not regulated  
 14.5 Environmental hazard Not applicable  
 14.6 Special Provisions None



# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 11-Oct-2022

Revision Number 2

**73402 73404 - Ruxolitinib**

<b>IATA</b>	<b>Not regulated</b>
<b>14.1 UN Number</b>	Not regulated
<b>14.2 UN proper shipping name</b>	Not regulated
<b>14.3 Transport hazard class(es)</b>	Not regulated
<b>14.4 Packing Group</b>	Not regulated
<b>14.5 Environmental hazard</b>	Not applicable
<b>14.6 Special Provisions</b>	None

## Section 15: REGULATORY INFORMATION

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

#### European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

#### Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

#### Persistent Organic Pollutants

Not applicable

**Ozone-depleting substances (ODS) regulation (EC) 1005/2009** Not applicable

#### International Inventories

<b>TSCA</b>	Does not comply
<b>DSL/NDL</b>	Does not comply
<b>EINECS/ELINCS</b>	Does not comply
<b>ENCS</b>	Does not comply
<b>IECSC</b>	Does not comply
<b>KECL</b>	Does not comply
<b>PICCS</b>	Does not comply
<b>AICS</b>	Does not comply

#### Legend:

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory  
**DSL/NDL** - Canadian Domestic Substances List/Non-Domestic Substances List  
**EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances  
**ENCS** - Japan Existing and New Chemical Substances  
**IECSC** - China Inventory of Existing Chemical Substances



# SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 11-Oct-2022

Revision Number 2

## 73402 73404 - Ruxolitinib

**KECL** - Korean Existing and Evaluated Chemical Substances  
**PICCS** - Philippines Inventory of Chemicals and Chemical Substances  
**AICS** - Australian Inventory of Chemical Substances

### 15.2. Chemical safety assessment

**Chemical Safety Report** No information available

## Section 16: OTHER INFORMATION

### Key or legend to abbreviations and acronyms used in the safety data sheet

#### Full text of H-Statements referred to under section 3

H302 - Harmful if swallowed

H318 - Causes serious eye damage

H361 - Suspected of damaging fertility or the unborn child

H373 - May cause damage to organs through prolonged or repeated exposure

#### Legend

SVHC: Substances of Very High Concern for Authorization:

#### Legend Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

TWA TWA (time-weighted average)

STEL

STEL (Short Term Exposure Limit)

Ceiling Maximum limit value

\*

Skin designation

Revision Date 11-Oct-2022

This material safety data sheet complies with the requirements of Regulation (EC) No. 1907/2006

#### Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text. STEMCELL Technologies Inc. shall not be held liable for any damage resulting from handling or from contact with the product.